TY - JOUR
T1 - CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
AU - Gambella, Massimiliano
AU - Carlomagno, Simona
AU - Raiola, Anna Maria
AU - Giannoni, Livia
AU - Ghiggi, Chiara
AU - Setti, Chiara
AU - Giordano, Chiara
AU - Luchetti, Silvia
AU - Serio, Alberto
AU - Bo, Alessandra
AU - Falco, Michela
AU - Della Chiesa, Mariella
AU - Angelucci, Emanuele
AU - Sivori, Simona
N1 - Funding Information:
Supported by the following grants: Fondazione AIRC IG 2017 Project Code 20312 (SS); PRIN 2017WC8499_004 (SS).
Publisher Copyright:
Copyright © 2022 Gambella, Carlomagno, Raiola, Giannoni, Ghiggi, Setti, Giordano, Luchetti, Serio, Bo, Falco, Della Chiesa, Angelucci and Sivori.
PY - 2022/2/24
Y1 - 2022/2/24
N2 - Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient’s immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.
AB - Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient’s immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.
KW - antibody-drug conjugates
KW - bispecific T cell engagers
KW - CAR-NK cells
KW - CAR-T cells
KW - engineered T cells
KW - genetic modification
KW - monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85126228016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126228016&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.837457
DO - 10.3389/fimmu.2022.837457
M3 - Review article
C2 - 35280988
AN - SCOPUS:85126228016
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 837457
ER -